Intrinsic Alpha

Company Snapshot

Kailera Therapeutics, Inc. investment report

Start with KLRA at a glance, then work through valuation, price history, fundamentals, management, competitors, and analyst expectations.

Kailera Therapeutics, Inc.

NASDAQ:KLRA

Biotechnology

Healthcare
$11.79 +2.66%

+$0.51 today

Market cap
$1.53B
Beta
0.00
52W Low $18.50High $28.23

Volume 0.42M

Average 0.80M

Intrinsic Value

KLRA Intrinsic Value

Start with the valuation result. Compare the current market price with the system DCF estimate, then use the supporting sections below to decide whether the assumptions are reasonable.

Kailera Therapeutics, Inc.

NASDAQ:KLRA

Intrinsic Alpha fair value

Locked

Current Price

$11.79

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.

Monitor KLRA

Get notified when the price moves into your range

Use alerts to turn the valuation into an action plan instead of checking the stock manually.

Price alerts

Get notified when KLRA drops below your target

Current price baseline

$11.79

Current price

Current price $11.79

Selected target$9.43

Sign in to activate price alerts.

Price History

How has KLRA traded over time?

Review how the market has priced Kailera Therapeutics, Inc. over time, alongside earnings and dividend events, before deciding whether today’s price is unusual.

Price history

Dividend-adjusted closing price

Period change

-54.65%

Period high

$26.00

Period low

$10.00

Latest

$11.79

Investment Notes

Capture the investment case

Write down the key idea, risks, and what would change your mind before testing the thesis against the fundamentals below.

My notes

Journal entries for KLRA

Sign in to keep notes

Keep your research and decisions in your personal journal.

Sign in / Sign up

Fundamental Analysis

Test company quality against your thesis

Work through profitability, revenue mix, financial position, cash generation, compounding numbers, and growth to see whether the business supports the investment case.

Earnings Quality

Follow revenue through to net income

Use the waterfall to see which costs, margins, and operating lines explain how much of each sales dollar becomes profit.

KLRA Earnings Waterfall · TTM

NASDAQ:KLRA · Revenue to Net Income

No earnings data available.

Revenue Mix

See which products and regions drive the business

Growth is easier to trust when you know where it comes from. Check whether one segment or region carries the company and how the mix is shifting.

Revenue by segment

Where KLRA earns its revenue, as reported in company filings

This company does not report revenue segments.

Financial Position

Check what supports the company underneath the income statement

The balance sheet shows liquidity, debt, asset mix, and book value quality before you rely on earnings or growth assumptions.

Balance Sheet

Assets, liabilities & equity

Cash & Equivalents$130.3M
Short-term Investments$786.4M
Other Current$12.4M
Total Current Assets$929.2M
PP&E (Net)$11.7M
Other Non-current$270.6M
Total Non-current Assets$282.2M
Total Assets$1.2B

Analysis

Selected assets total $1.2B for Latest. The largest visible component is Short-term Investments at $786.4M, about 64.9% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.

Cash Generation

Test whether profit turns into cash

Free cash flow connects accounting earnings to owner earnings, showing how much cash remains after reinvestment needs.

Free Cash Flow

Net Income to FCF bridge

Cash Flow Statement

FY2025

= Net Income-$149.0M
+ D&A$310.0K
+ Stock-Based Comp$10.9M
+ Deferred Tax$0
+ Working Capital$16.8M
+ Other Non-Cash$714.0K
= Operating Cash Flow-$120.2M
- Capex-$2.1M
= Free Cash Flow-$122.3M

Analysis

FY2025 free cash flow is -$122.3M. FCF conversion is 82.1% of net income. Operating cash flow was -$120.2M, with capex of -$2.1M. The largest bridge item is Working Capital at $16.8M.

Quality Snapshot

Check the numbers that compound value

Check whether earnings, revenue, equity, cash, and returns on capital are moving in the same direction as your written thesis.

Big Five Numbers

CAGR by period · ROIC shows average

Metric 10yr 5yr3yr1yr
EPS
N/AN/AN/AN/A
Revenue
N/AN/AN/AN/A
Equity
N/AN/AN/AN/A
Cash
N/AN/AN/AN/A
ROIC
N/AN/AN/A-24.5%

Analysis

Latest growth is strongest in ROIC at -24.5% and weakest in ROIC at -24.5%.

Growth Profile

Compare historical growth with forward expectations

Strong past growth matters more when analysts still expect the business to expand without relying on one temporary driver.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A1 analysts
RevenueN/AN/AN/A
N/A3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Analysis will appear once historical growth or forward estimates are available for this company.

Management

Judge how Kailera Therapeutics, Inc. allocates capital

Review returns on capital, owner payouts, dividend durability, insider activity, and the leadership responsible for these decisions.

Capital Efficiency

Returns on equity, invested capital, and assets help separate durable operators from businesses that only grow by adding more capital.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

41.8%

avg 41.8%

ROIC

-24.5%

avg -24.5%

ROA

-21.5%

avg -21.5%

Analysis

ROE is currently the strongest return metric at 41.8% versus its period average of 41.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Dividend Record

A dividend is more useful when growth, payout ratio, and free cash flow support the current yield.

Dividends

Dividend history, growth & yield

Dividends

Yield

—

Annual Div/Share

$0.00

Payout Ratio

—

Frequency

—

Shareholder Yield

0.00%

Next Ex-Date

Not announced

Next Payment

—

Analysis

The current indicated dividend yield is not available.

Owner Returns

Dividends, buybacks, and debt paydown show whether excess cash is being reinvested, returned, or used to strengthen the balance sheet.

Shareholder Returns

Dividend, buyback & debt paydown yields

Management

Dividend Yield (TTM)

0.00%

Buyback Yield (TTM)

0.00%

Debt Paydown (TTM)

0.00%

Total Yield (TTM)

0.00%

Showing limited history. Sign in for more

Analysis

Total TTM shareholder yield is 0.00% including 0.00% from debt paydown. The largest current contributor is dividends at 0.00%, which helps show whether capital returns are coming from direct cash payouts, share count reduction, or balance sheet cleanup.

Insider Activity

Insider transactions add context to ownership incentives and can reveal when leadership behavior diverges from the public investment case.

Insider Trading

SEC Form 4 transactions — last 12 months

Management

Buys

5

$326.75M

Sells

0

$0.00

Net Transaction Value

+$326.75M

Net buying

Most Active

BAIN CAPITAL INVESTORS LLC

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Apr 20, 26

BAIN CAPITAL INVESTORS LLC

Indirect

Buy$134.4M
Apr 20, 26

Koppel Adam

Indirect

Buy$25M
Apr 20, 26

Bain Capital Life Sciences Investors, LLC

Indirect

Buy$25M
Apr 20, 26

Kaplan Andrew T.

Indirect

Buy$134.4M
Apr 20, 26

RTW INVESTMENTS, LP

Indirect

Buy$8M

Summary

Insiders reported 5 buys worth $326.75M and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $326.75M. BAIN CAPITAL INVESTORS LLC was the most active insider with 1 transactions.

Leadership

Leadership context helps you judge who is responsible for strategy, capital allocation, and execution.

Management

Key executives, compensation & ownership

View management
NameTitleCompensationAgeShares OwnedOwnership %

Jamie Beth Coleman

Chief Commercial OfficerUSD 911.28K4875.00K0.06%

Ronald C. Renaud Jr.

President, CEO & DirectorUSD 863.87K5738.09K0.03%

Paul Douglas Burgess

Chief Operating & Business OfficerUSD 670.19K52——

Kathleen Tregoning

Chief Corporate Affairs Officer—55175.00K0.14%

Corey Manchester

Treasurer————

Scott Wasserman

Chief Medical Officer—56——

Maura Gavaghan

Vice President of Corporate Communications & Investor Relations————

Scott Akamine

Chief Legal Officer & Secretary—4160.00K0.05%

Paula A. Cloghessy SHRM-SCP SPHR

Chief People Officer—54——

Douglas W. Pagan

Chief Financial Officer—54100.00K0.08%

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 6, 2026.

Alternatives to KLRA

Compare Kailera Therapeutics, Inc. with similar companies

A stock can look attractive in isolation and still be less compelling than a peer. Check competitors before committing to the thesis.

Analysts

What Wall Street expects from KLRA

Compare consensus price targets and ratings with your own valuation to understand how much optimism the market is already pricing in.

Analyst Targets

See where analysts expect KLRA to trade next

Compare the latest consensus target range with the current share price to understand how much upside or downside Wall Street is pricing in.

Wall Street price targets

1-year price history with analyst consensus target

Growth

Unlock analyst target range

Sign in free to see low, average, high targets and implied upside for KLRA.

Sign in free

Analyst Ratings

How analysts rate KLRA today

See the buy, hold, and sell split behind the consensus and whether recent rating changes lean toward upgrades or downgrades.

Analyst ratings

Buy, hold, and sell recommendations and recent rating changes

Unlock analyst ratings

Sign in free to see the buy/hold/sell breakdown and recent rating changes for KLRA.

Sign in free

Company Overview

Understand how Kailera Therapeutics, Inc. makes money

Ground the financial evidence in the company profile, business description, and key facts.

Key Information

Filings
NameKailera Therapeutics, Inc.
TickerKLRA
ExchangeNASDAQ Global Select
IPO DateApr 17, 2026
IndustryBiotechnology
SectorHealthcare
Market Cap$1.53B
Shares Out129.57M
LocationWaltham, MA, US

Stock Analysis

Turn the KLRA report into your next decision

Record your conclusion, evidence, and concerns in a structured analysis workspace.

Investment analysis

Turn KLRA research into a decision

Work through Know the Business, Test the Moat, Management, and Intrinsic Value in one private, repeatable checklist.

NASDAQ:KLRA
Know the Business
Test the Moat
Management
Intrinsic Value

Sign in on the next page to save a private analysis.

Start analysis

FAQ

Common questions about KLRA

Resolve the remaining questions before moving into the detailed workspaces.

Explore

Continue your research

Open the detailed valuation, financial, health, and management workspaces.